Pasithea Therapeutics (KTTAW) Competitors $0.03 0.00 (-16.33%) As of 01:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends KTTAW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUWShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Celularity 180 Life Sciences (NASDAQ:ATNFW) and Pasithea Therapeutics (NASDAQ:KTTAW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk. Does the media prefer ATNFW or KTTAW? In the previous week, 180 Life Sciences and 180 Life Sciences both had 1 articles in the media. 180 Life Sciences' average media sentiment score of 1.89 beat Pasithea Therapeutics' score of 1.87 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Very Positive Pasithea Therapeutics Very Positive Does the MarketBeat Community believe in ATNFW or KTTAW? 180 Life Sciences and Pasithea Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/APasithea TherapeuticsN/AN/A Which has preferable valuation & earnings, ATNFW or KTTAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/APasithea Therapeutics$486.56KN/AN/AN/AN/A Is ATNFW or KTTAW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Pasithea Therapeutics N/A N/A N/A Summary180 Life Sciences and Pasithea Therapeutics tied by winning 1 of the 2 factors compared between the two stocks. Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTAW vs. The Competition Export to ExcelMetricPasithea TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$178.34M$5.62B$9.14BDividend YieldN/A3.64%5.36%3.98%P/E RatioN/A138.2789.6917.66Price / SalesN/A18,255.231,219.4081.09Price / CashN/A13.0144.3437.71Price / BookN/A8.975.134.73Net IncomeN/A-$20.89M$118.85M$225.42M7 Day PerformanceN/A7.51%1.87%-0.44%1 Month PerformanceN/A9.03%7.96%3.57%1 Year PerformanceN/A105.35%26.70%19.20% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAWPasithea TherapeuticsN/A$0.03-16.3%N/A+200.0%$0.00$486,559.000.003Positive NewsGap DownATNFW180 Life SciencesN/A$0.01flatN/A+73.1%$0.00N/A0.007Gap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.03-1.0%N/A-30.0%$0.00N/A0.002AIMDWAinosN/A$0.15+51.5%N/A+156.2%$0.00$40,633.000.0040ALVOWAlvotechN/A$2.81-1.1%N/A-28.5%$0.00$391.87M0.004Short Interest ↓Gap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.06flatN/A+39.1%$0.00N/A0.004BFRIWBiofronteraN/A$0.06-1.1%N/A+689.5%$0.00$35.36M0.0070BTMDWbioteN/A$0.44-11.2%N/AN/A$0.00$193.06M0.00N/ABCTXWBriaCell TherapeuticsN/A$0.14+0.7%N/A-90.6%$0.00N/A0.008Short Interest ↑CELUWCelularityN/A$0.06+0.3%N/A+167.9%$0.00$48.20M0.00220 Related Companies and Tools Related Companies 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Biofrontera Alternatives biote Alternatives BriaCell Therapeutics Alternatives Celularity Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KTTAW) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
